Citations

Mayo Clinic

Showing 10 of 108599 citations.

Effect of a near-universal hospitalization-based prophylaxis regimen on annual number of venous thromboembolism events in the US
Heit, John A. , Crusan, Daniel J. , Ashrani, Aneel A. , Petterson, Tanya M. , Bailey, Kent R.

Blood | May 9, 2017 | Volume: 130 | Issue: 2 | Pages: 109-114

10.1182/blood-2016-12-758995 | PMID 28483763 Get It

Key PointsApproximately 500 000 US VTE events occur annually; approximately one-half are related to current or recent hospitalization. VTE attack rates (2005-2010) did not change despite near-universal in-hospital VTE prophylaxis, possibly due to short prophylaxis duration.
Development of High-Grade Daptomycin Resistance in a Patient Being Treated for Corynebacterium striatum Infection
AJMAL, SAIRA, Saleh, Omar Abu , Beam, Elena

Antimicrobial Agents and Chemotherapy | May 9, 2017 | Volume: 61 | Issue: 7 | Pages: No page available

10.1128/aac.00705-17 | PMID 28483949 Get It

Intramyocellular Ceramides: Subcellular Concentrations and Fractional De Novo Synthesis in Postabsorptive Humans
Chung, Jin Ook , Koutsari, Christina , Błachnio‐Zabielska, Agnieszka , Hames, Kazanna C. , Jensen, Michael D.

Diabetes | May 9, 2017 | Volume: 66 | Issue: 8 | Pages: 2082-2091

10.2337/db17-0082 | PMID 28483801 Get It

We investigated the relationship between insulin resistance markers and subsarcolemmal (SS) and intramyofibrillar (IMF) ceramide concentrations, as well as the contribution of plasma palmitate (6.5-h infusion of [U-13C]palmitate) to intramyocellular ceramides. Seventy-six postabsorptive men and women had muscle biopsies 1.5, 6.5, and 24 h after starting the tracer infusion. Concentrations and enrichment of muscle ceramides were measured by liquid chromatography-tandem mass spectrometry. We found that HOMA of insulin resistance, plasma insulin, and triglyceride concentrations were positively correlated with SS C16:0 and C18:1 ceramide, but not SS C14:0-Cer, C20:0-Cer, C24:0-Cer, and C24:1-Cer concentrations; IMF ceramide concentrations were not correlated with any metabolic parameters. The fractional contribution of plasma palmitate to 16:0 ceramide was greater in SS than IMF (SS, 18.2% vs. IMF, 8.7%; P = 0.0006). Plasma insulin concentrations correlated positively with the fractional contribution of plasma palmitate to SS 16:0 ceramide. The fractional contribution of plasma palmitate to intramyocellular SS 16:0 ceramide was positively correlated with SS C16:0 ceramide concentrations (γ = 0.435; P = 0.002). We conclude that skeletal muscle SS ceramides, especially C16 to C18 chain lengths and the de novo synthesis of intramyocellular ceramide from plasma palmitate are associated with markers of insulin resistance.
Clinical Reasoning: A 45-year-old man with weakness and myalgia after orthopedic surgery
Campo, Rocio Vazquez Do , Siegel, Jason , Dimberg, Elliot L., Vazquez do Campo, Rocio, Dimberg, Elliot, Goldstein, Eric , Vazquez Do Campo, Rocio

Neurology | May 8, 2017 | Volume: 88 | Issue: 19 | Pages: No page available

10.1212/wnl.0000000000003914 | PMID 28483995 Get It

Personalizing the Use of Circulating Microparticle-Associated Tissue Factor As a Biomarker for Recurrent Thrombosis in Patients With Cancer
Braggio, Esteban , Cesarman-Maus, Gabriela, Fonseca, Rafaël , Cesarman‐Maus, Gabriela , Braggio, Esteban

Journal of Clinical Oncology | May 8, 2017 | Volume: 35 | Issue: 19 | Pages: 2217-2218

10.1200/jco.2017.72.5341 | PMID 28481704 Get It

Abstract B45: Endometrial cancer microbiome signature and its implications for carcinogenesis
Hokenstad, Alexis, Distad, Tammy, Cheek, Heidi, Keeney, Gary L., Creedon, Douglas J., Nelson, Heidi D , Mariani, Andrea , Walther-António, Marina , Chen, Jun , Multinu, Francesco , Mariani, Andrea , Chia, Nicholas

Clinical Cancer Research | May 8, 2017 | Volume: 23 | Issue: 1_Supplement | Pages: B45-B45

10.1158/1557-3265.pmccavuln16-b45 Get It

Abstract Endometrial cancer studies have led to a number of well-defined but mechanistically unconnected genetic and environmental risk factors. One of the emerging modulators between environmental triggers and genetic expression is the microbiome. Because of the inflammatory display in endometrial cancer, we set out to inquire about the composition of the uterine microbiome and its putative role in endometrial cancer. We undertook a pilot study of the microbiome in 238 samples taken from different locations along the entire female reproductive tract in hysterectomy patients with endometrial cancer (n=17), patients with endometrial hyperplasia (n=4) and patients afflicted with a benign uterine condition (n=10). Samples were collected aseptically both in the operating room and the pathology laboratory. Following DNA extraction, the 16S rDNA (V3-V5 region) microbial gene was amplified and sequenced to identify the microbiota present. The microbiome sequencing revealed a structural microbiome shift in the cancer and hyperplasia cases, distinguishable from the benign cases (p=0.01). Several taxa were found to be significantly enriched in samples belonging to the endometrial cancer cohort: Firmicutes (Anaerostipes, ph2, Dialister, Peptoniphilus, 1-68, Ruminococcus, and Anaerotruncus), Spirochaetes (Treponema), Actinobacteria (Atopobium), Bacteroidetes (Bacteroides and Porphyromonas), and Proteobacteria (Arthrospira). Of particular relevance, the simultaneous presence of Atopobium vaginae and an uncultured representative of the Porphyromonas sp. (99% match to P.somerae) were found to be predictive of the disease status (sensitivity 73-93%; specificity 67-90%, AUC 0.918). Sensitivity is increased to 100% if combined with a high vaginal pH (>4.5), although specificity is decreased to 60%. Although our numbers are low, the microbiome signature of hyperplasia was even more distinct from benign disease than endometrial cancer itself. This is suggestive of an early microbiome role in the disease. Given the pathogenic profile of the identified microorganisms these findings raise the possibility of a microbiome role in the etiology or progression of endometrial cancer that should be further investigated. Citation Format: Marina Walther-Antonio, Jun Chen, Francesco Multinu, Alexis Hokenstad, Tammy Distad, Heidi Cheek, Gary Keeney, Douglas Creedon, Heidi Nelson, Andrea Mariani, Nicholas Chia. Endometrial cancer microbiome signature and its implications for carcinogenesis. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer; May 16-19, 2016; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2017;23(1_Suppl):Abstract nr B45.
Authors' Response to Bozkurt et al.
Rivera, Marcelino , Krambeck, Amy E.

Journal of Endourology | May 8, 2017 | Volume: 31 | Issue: 5 | Pages: 546-546

10.1089/end.2017.29028.riv | PMID 28481689 Get It

BLAST-AHF: insights into biased AT1 ligands and heart failure. Beginning of the end or end of the beginning?
Sugihara, Shinobu , Burnett, John C.

European Heart Journal | May 8, 2017 | Volume: 38 | Issue: 30 | Pages: 2374-2376

10.1093/eurheartj/ehx276 | PMID 28575396 Get It

Acute and midterm results following perventricular device closure of muscular ventricular septal defects: A multicenter PICES investigation
Gray, Robert G. , Menon, Shaji C. , Johnson, Joyce T. , Bingler, Michael, Breinholt, John P. , Kenny, Damien , Lozier, John S. , Murphy, Joshua, Sathanandam, Shyam , Taggart, Nathaniel W. , Trucco, Sara M. , Goldstein, Bryan H. , Gordon, Brent M. , Armstrong, Aimee K. , Taggart, Nathaniel W , Goldstein, Bryan H

Catheterization and Cardiovascular Interventions | May 8, 2017 | Volume: 90 | Issue: 2 | Pages: 281-289

10.1002/ccd.27121 | PMID 28805027 Get It

ObjectivesTo describe acute and mid‐term results of hybrid perventricular device closure of muscular ventricular septal defects (mVSDs).BackgroundPerventricular device closure of mVSDs can mitigate technical limitations of percutaneous closure and need for cardiopulmonary bypass or ventriculotomy with a surgical approach.MethodsThis is a multicenter retrospective cohort study of patients undergoing hybrid perventricular mVSD device closure from 1/2004 to 1/2014. Procedural details, adverse events, outcomes, and follow‐up data were collected. Patients were divided into two groups: (1) simple (mVSD closure alone) and (2) complex (mVSD closure with concomitant cardiac surgery).ResultsForty‐seven patients (60% female) underwent perventricular mVSD device closure at a median age of 5.2 months (IQR 1.8–8.9) and weight of 5.1 kg (IQR 4.0–6.9). Procedural success was 91% [100% (n = 22) simple and 84% (n = 21/25) complex]. Adverse events occurred in 19% (9/47) [9% (2/22) simple and 28% (7/25) complex]. Hospital length of stay (LOS) was shorter in the simple vs. complex group (4 vs. 14 days, P < 0.01). At mid‐term follow‐up of 19.2 months (IQR 2.3–43) 90% of pts had complete mVSD closure; none developed late heart block, increased atrioventricular (AV) valve insufficiency or ventricular dysfunction.ConclusionsPerventricular device closure of simple mVSD was associated with a high rate of procedural success, few adverse events, and short hospital LOS. Procedural adverse events were associated with the presence of concomitant complex surgery. Residual mVSD, AV valve insufficiency, or ventricular dysfunction were uncommon at mid‐term follow‐up. © 2017 Wiley Periodicals, Inc.
Comparison of the hospital costs for two-stage reimplantation for deep infection, single-stage revision and primary total elbow arthroplasty
Wagner, Eric R. , Ransom, Jeanine E. , Kremers, Hilal Maradit , Morrey, Mark, Sanchez-Sotelo, Joaquin, Morrey, Mark E. , Sánchez‐Sotelo, Joaquín , Wagner, Eric R , Maradit Kremers, Hilal

Shoulder & Elbow | May 8, 2017 | Volume: 9 | Issue: 4 | Pages: 279-284

10.1177/1758573217706364 | PMID 28932285 Get It

Background The purpose of the present study was to determine the cost of two-stage reimplantation for the treatment of deep infection after total elbow arthroplasty (TEA) and compare this with primary and aseptic revision TEA. Methods Three hundred and seventy-one primary TEA and 286 revision TEAs (including 47 elbows requiring two-stage reimplantation) were performed. Total direct medical costs during each hospitalization were obtained from our institutional research database and compared for three groups: primary TEA, revision for nonseptic reasons and two-stage reimplantation for deep infection. Results The mean cost of an uncomplicated primary TEA and aseptic revision TEA was $18,464 and $18,796, respectively. The mean overall cost associated with two-stage reimplantation increased to $34,286. Two-stage reimplantation increased both Part A (hospital costs) and Part B (professional costs). The mean Part A cost for septic revision TEA was $29,102 versus $15,844 for primary TEA. The mean Part B cost for septic revision TEA was $5,184 versus $2,621 for primary TEA. Conclusions Two-stage reimplantation for treatment of an infected TEA costs 186% the hospital cost of a primary uncomplicated or aseptic revision TEA. The overall cost to society is even greater if we take into account the cost of antibiotic therapy in between stages and lost days from work.